<DOC>
	<DOC>NCT00763555</DOC>
	<brief_summary>This is a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in subjects with plaque-type psoriasis.</brief_summary>
	<brief_title>Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Subject has a diagnosis of plaquetype psoriasis up to 20% of body surface area (BSA) involved excluding the scalp, with a Global Severity Score of at least 3 (moderate) at Screening Subject presents with a representative target lesion that is at least 16 cmÂ² in area, is located on the nonbony areas of the skin, has a Scaling Score up to 2 (moderate), has a DSS of at least 4 Other type of psoriasis (other than plaque) Significant abnormal lab findings Hypercalcemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>spray</keyword>
	<keyword>calcitriol</keyword>
</DOC>